1 – 5 of 5
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2022
-
Mark
RNA sequencing-based single sample predictors of molecular subtype and risk of recurrence for clinical assessment of early-stage breast cancer
Vallon-Christersson, J. LU
; Staaf, J.
LU
; Häkkinen, J.
LU
; Hegardt, C.
LU
; Saal, L.
LU
; Ehinger, A.
LU
; Larsson, C.
LU
; Loman, N.
LU
; Rydén, L.
LU
and Malmberg, M.
, et al.
(2022)
In Annals of Oncology
33(Suppl 3).
p.144-145
- Contribution to journal › Published meeting abstract
- 2016
-
Mark
Targeted sequencing of BRCA1 and BRCA2 across a large unselected breast cancer cohort suggests that one-third of mutations are somatic
Winter, C LU ; Nilsson, M P LU ; Olsson, E LU ; George, A M LU ; Chen, Y LU ; Kvist, A LU
; Törngren, T
LU
; Vallon-Christersson, J
LU
; Hegardt, C
LU
and Häkkinen, J
LU
, et al.
(2016)
In Annals of Oncology
27(8).
p.8-1532
- Contribution to journal › Article
- 2013
-
Mark
Serum thymidine kinase activity compared with CA 15-3 in locally advanced and metastatic breast cancer within a randomized trial
- Contribution to journal › Article
- 2012
-
Mark
Individually tailored treatment with epirubicin and paclitaxel with or without capecitabine as first-line chemotherapy in metastatic breast cancer: a randomized multicenter trial
- Contribution to journal › Article
- 2009
-
Mark
Validation of the predictive value of tissue inhibitor of metalloproteinases-1 for the response to first-line chemotherapy in metastatic breast cancer.
- Contribution to journal › Published meeting abstract